Comparing the efficacy and safety of IL-17 inhibitors for treatment of moderate-to-severe psoriasis: a randomized double blind pilot study with a review of literature
Main Authors: | Nawaf Almutairi, Bayoumy Eassa |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2020-01-01
|
Series: | Advances in Dermatology and Allergology |
Subjects: | |
Online Access: | https://www.termedia.pl/Comparing-the-efficacy-and-safety-of-IL-17-inhibitors-for-treatment-of-moderate-to-severe-psoriasis-a-randomized-double-blind-pilot-study-with-a-review-of-literature,7,39535,1,1.html |
Similar Items
-
Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis
by: Mary Catherine G. Pangilinan, et al.
Published: (2020-08-01) -
Generalized hypertrichosis associated with the use of interleukin 17 blockers in 2 patients with psoriasis
by: Luis E. Sánchez-Dueñas, MD, et al.
Published: (2020-07-01) -
Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study
by: Shany Sherman, et al.
Published: (2020-12-01) -
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01) -
IL-17A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience
by: Shany Sherman, et al.
Published: (2019-05-01)